Measles Record, Europe's Heat Crisis, and a Prostate Cancer Milestone
The US logs its worst measles surge in 35 years, Europe faces a new heat wave, and a landmark prostate cancer trial shifts the care standard.
By Dr. Asher Knippel
The week of 9 August brought a cascade of public-health alerts alongside two encouraging clinical developments — a reminder that trust in evidence-based medicine is always upstream of outcomes.
Thursday, 6 August: US Measles Cases Reach a 35-Year High
As of 6 August 2026, the CDC has confirmed 2,465 measles cases across 47 jurisdictions, the highest annual total since 1991 and already surpassing all of 2025 with four months of the calendar year still to run. Ninety-four percent of those cases — 2,309 people — are linked to 38 active outbreaks, and 146 patients (6 percent) have required hospitalisation. Public health officials trace the surge directly to a decline in MMR vaccination coverage, which slipped from 95.2 percent in the 2019–2020 school year to 92.5 percent in 2024–2025, just below the 95 percent threshold epidemiologists regard as necessary for community protection. With peak summer travel underway, the CDC warns that case counts are likely to keep climbing through September. Measles was declared eliminated from the United States in 2000; the current trajectory puts that status at risk.
Thursday, 6 August: Landmark Lancet Trial Advances Lutetium PSMA Therapy in Prostate Cancer
Results of the PSMAddition phase 3 randomised controlled trial, published in The Lancet, show that adding lutetium-177 PSMA-617 to standard hormone therapy significantly improves outcomes in men with PSMA-positive metastatic hormone-sensitive prostate cancer — an earlier, more treatable stage of the disease than where the drug has previously been approved. The trial enrolled 1,144 patients across multiple international sites, randomising 572 to receive six cycles of the radioligand therapy alongside androgen-deprivation therapy and an androgen receptor pathway inhibitor, and 572 to receive hormone therapy alone; 85.6 percent of patients in the experimental arm completed all six cycles. The drug works by binding to PSMA — a protein expressed on the surface of most prostate cancer cells — and delivering targeted beta radiation directly to the tumour and its metastatic deposits. Investigators from Weill Cornell Medicine, NewYork-Presbyterian, and Memorial Sloan Kettering say the results may change the standard of care for PSMA-positive disease, moving lutetium-177 PSMA-617 (commercially available as Pluvicto) from a late-line rescue therapy to an earlier, more impactful treatment option.
Ongoing Since July: Cyclospora Parasite in Lettuce Sickens Thousands Across 15 US States
A foodborne outbreak of Cyclospora cayetanensis — a single-celled intestinal parasite — linked to shredded iceberg lettuce sourced from Taylor Farms de México and served at Taco Bell locations has spread to 15 states, with at least 6,358 confirmed illnesses, 278 hospitalisations, and two deaths in Michigan. Taylor Farms voluntarily recalled the affected products on 17 July 2026, covering Marketside-brand "Iceberg Salad" and "Shredded Lettuce" with Best If Used By dates of 18 July through 3 August. Cyclospora infections typically present with prolonged watery diarrhoea, fatigue, and abdominal cramping lasting two to six weeks without treatment; trimethoprim-sulfamethoxazole (co-trimoxazole) is the recommended antibiotic course. The FDA's investigation is ongoing and no confirmed positive product test results had been returned as of 5 August. Anyone who purchased the recalled products should discard them immediately and not consume them.
Saturday, 8 August: A New Heat Dome Builds Over Europe and the Mediterranean
A second major heat event is forecast to engulf the Mediterranean and much of Europe in the days ahead, with daytime temperatures expected to exceed 40°C across Iberia, southern France, and Italy. Italy's health ministry has placed all 27 of its monitored cities — including Rome, Naples, Venice, and Bologna — on red alert. This follows a June 2026 wave that killed at least 1,300 people across Europe, with researchers estimating 10,000 excess deaths attributable to the full summer so far. A rapid attribution analysis by World Weather Attribution found that fossil fuel emissions have raised peak European summer temperatures by at least 3–4°C compared to a pre-industrial baseline, making a heat event of this magnitude essentially impossible without human-caused climate change. For Cyprus and the eastern Mediterranean — where residential air conditioning is less widespread than in northern Europe and outdoor work is common through August — the risk is acute. The Cyprus Ministry of Health advises people aged 65 and older, pregnant women, and those with cardiovascular or respiratory conditions to remain indoors between 11:00 and 17:00, drink water every 15–20 minutes regardless of thirst, and never leave children or pets unattended in vehicles.
Upcoming Decision: A Single-Tablet HIV Regimen Approaches FDA Review
Gilead Sciences' investigational combination of bictegravir (75 mg) and lenacapavir (50 mg) — a once-daily single-tablet regimen for adults with HIV who are already virologically suppressed — carries a PDUFA action date of 27 August 2026, with priority review granted. The pill pairs bictegravir, an integrase strand transfer inhibitor already familiar from the widely used Biktarvy, with lenacapavir, a first-in-class capsid inhibitor that disrupts multiple stages of the HIV life cycle and carries an exceptionally high genetic barrier to resistance. Data from the ARTISTRY-1 and ARTISTRY-2 trials showed that adults who switched from their existing multi-tablet regimen to this single-tablet combination maintained virological suppression across diverse groups, including people with complex treatment histories, multiple comorbidities, and prior antiretroviral drug resistance. If approved, BIC/LEN would be the first single oral tablet to combine a capsid inhibitor with an integrase inhibitor, offering a simplified option for the estimated 1.2 million people living with HIV in the United States.
The content in this article is journalistic and is not a substitute for professional medical advice. Readers should consult a qualified clinician before making any change to their treatment, medication, or health routines.